Provenge (sipuleucel-T) is an autologous cellular immunotherapy, which involves removing immune cells from a patient's blood, priming them to recognise prostate cancer, and then returning them to ...

The April 29 approval of Seattle-based Dendreon's prostate cancer vaccine, Provenge (sipuleucel-T), is being hailed as a victory for cancer immunotherapy. For Dendreon, the US Food and Drug ...

In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous ... or minimally symptomatic metastatic castration-resistant prostate cancer. It is the first therapeutic cancer vaccine to receive ...

Sipuleucel-T (Provenge; Dendreon ... shown to potentiate immune responses and mitigate immune tolerance to prostate cancer antigens. Chemotherapy plus vaccine: Certain chemotherapy agents have ...

Other, newer treatments include immunotherapy drugs known as checkpoint inhibitors; a vaccine for prostate cancer that has spread to other parts of the body (sipuleucel-T; Provenge); treatments ...

It’s been 13 years since the FDA approved its first therapeutic vaccine – Dendreon Pharma’s Provenge (sipuleucel-T) for prostate cancer, which was not a commercial success – and since then ...

A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

Provenge (sipuleucel-T) is created by exposing the immune cells of someone with prostate cancer to a protein that “teaches” ...